Related Experiment Video
Updated: Jul 5, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Identification of potential bladder cancer drug targets through Mendelian randomization and molecular docking
Chengwei Bi1, Kexun Li2, Yong Yang1
1Department of Urology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China.
Abstract:
Bladder cancer is a common and lethal malignancy with high treatment costs due to frequent recurrence and prolonged therapy. Despite therapeutic advances, many patients develop drug-resistant metastatic disease, underscoring the need for new treatments. Using the STROBE-MR guidelines, we performed Mendelian randomization with cis- expression quantitative trait loci (eQTLs) from the eQTLGen Consortium (n = 31,684) as exposures. Two independent cohorts served as discovery and replication sets for target identification. Drug prediction and molecular docking were applied to validate the targets. Twelve significant drug targets were identified. Phenome-wide association study revealed additional associations of NDST1 and HMGCR with proteomic traits and health service use, respectively. Molecular docking confirmed strong binding for available protein structures. Our study identified 12 promising drug targets for bladder cancer and suggests that MR-based prioritization may improve clinical trial success and reduce development costs.
Insights
This study identified 12 novel drug targets for bladder cancer using Mendelian randomization. This approach may accelerate the development of new bladder cancer treatments and reduce costs.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Bladder cancer presents significant challenges due to recurrence, metastasis, and drug resistance.
- Existing treatments are often costly and insufficient for advanced disease, necessitating novel therapeutic strategies.
Purpose of the Study:
- To identify novel drug targets for bladder cancer using a Mendelian randomization approach.
- To validate identified targets through drug prediction and molecular docking.
- To explore potential associations of identified targets with proteomic traits and health service utilization.
Main Methods:
- Mendelian randomization (MR) was employed using cis-expression quantitative trait loci (eQTLs) from the eQTLGen Consortium as exposures.
- Two independent cohorts were utilized for target discovery and replication.
- Drug prediction algorithms and molecular docking simulations were performed for target validation.
Main Results:
- Twelve significant drug targets for bladder cancer were successfully identified.
- The genes NDST1 and HMGCR showed additional associations with proteomic traits and health service use, respectively.
- Molecular docking confirmed robust binding affinities for the identified protein targets.
Conclusions:
- The study successfully identified 12 promising drug targets for bladder cancer.
- Mendelian randomization-based prioritization offers a potential strategy to enhance clinical trial success rates.
- This approach may lead to reduced drug development costs for new bladder cancer therapies.
